Kornimate/medical-research-clean huggingface dataset:
atomoxetine in patients with tourette's syndrome

Conditions: Tourette Syndrome

Summary: the purpose of this pilot study is to evaluate the effects of atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with tourette's syndrome.

high impulsivity characterizes severe forms of tourette's syndrome, in which motor and vocal tics are associated with various neuropsychiatric disorders as compulsive disorders, difficult to manage and impairing quality of life of patients and their family. previous preclinical study and clinical studies in attention-deficit hyperactivity disorder and parkinson's disease demonstrate that atomoxetine, a selective noradrenaline reuptake inhibitor, improves response inhibition in high impulsive individuals. however, there is no suffisant data in tourette's syndrome. the purpose of this pilot study is to evaluate the effects of atomoxetine on impulsivity in 10 to 35 years old patients with tourette's syndrome.

Eligibility criteria:
inclusion criteria: * high impulsive patients, aged 10-35 years old, diagnosed for tourette's syndrome as defined by the dsm-iv, never treated by atomoxetine * the use of effective contraception or abstinence for subjects of reproductive age * written informed consent exclusion criteria: * patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to tourette's syndrome criteria. * actual severe depression * allergy to one of the constituents * severe cardiovascular or cerebrovascular diseases, pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma * imao treatment discontinued less than 2 months or contra-indicated associated treatment

Keywords: impulsivity
feasibility of evaluating gene alteration analysis using samples obtained by ebus-tbna in patients with lung cancer

Conditions: Lung Cancer

Summary: lung cancer is the leading cause of death in the world. overall 5-year survival rate is fewer than 10% and the effectiveness of conventional chemotherapy is limited. the new knowledge shows the correlation between genetic alteration and effective of chemotherapy. therefore non-surgical modalities to obtain tumor specimens for genetic alteration analysis are particularly critical in lung cancer, since many patients have advanced disease at the time of first presentation, and are therefore not eligible for radical surgery. endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) samples obtained during diagnosis of lung cancer can be used for molecular analysis that will predict response to treatment and prognosis. in this study, we will detect specific target molecules related to the effectiveness of treatment (surgery, chemotherapy, radiotherapy) and prognosis in patients with lung cancer using ebus-tbna samples and its combined with xenograft technology.


Eligibility criteria:
inclusion criteria: * age 18 years or older. * patients with confirmed or suspected lung cancer who require ebus-tbna as part of their staging investigations of the mediastinum will be considered for the trial. * patients with undiagnosed enlarged lymph nodes in the mediastinum suspicious for lung cancer in which a tissue diagnosis is required. exclusion criteria: * patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy. * patients where there is a high clinical suspicion of lymphoma.

Keywords: patients undiagnosed enlarged lymph nodes
omega-3 fatty acid dietary intervention (o3di)

Conditions: Hypertriglyceridemia

Summary: elevated cholesterol, including triglyceride levels, can lead to the development of cardiovascular disease in adulthood. a diet that is rich in omega-3 fatty acids (o3fa) can improve triglyceride levels in a way that is safe and does not require medication. this is a single-center, prospective, unblinded, randomized-controlled dietary intervention study to assess the impact of an omega-3 fatty acid diet compared to a standard lifestyle intervention on serum triglyceride in patients with hypertriglyceridemia. the study consists of an 8-week dietary treatment period followed by an 8-week observation period.


Eligibility criteria:
inclusion criteria: 1. male or female patients who are 10 -17 years of age 2. bmi greater than or equal to the 85th percentile 3. clinical serum triglyceride level \>150 mg/dl and \< 500 mg/dl performed between 3 months and 1 week prior to study visit 1 4. ability to follow the study procedures and adhere to the diet counseling recommendations 5. written parental permission and assent are obtained prior to any research procedures exclusion criteria: 1. type 2 dm (hemoglobin a1c \>6.6%) 2. isotretinoin use 3. chronic kidney disease (ckd) 4. uncontrolled hypothyroidism 5. warfarin use 6. liver disease (nafld is allowed) 7. renal disease 8. corticosteroid use 9. omega-3 fatty acid use (prescription or supplement) 10. allergy to fish and/or nuts 11. currently pregnant or planning to become pregnant during the course of this trial - confirmed by date of lmp/querying family 12. any significant medical condition which the investigator believes would interfere with participation in this study
effect of agar administration on defecation and fecal condition in chronic constipated patients

Conditions: Constipation

Summary: the administration of agar jelly may increase the number of defecation and the volume of feces, and then may improve fecal condition in chronic constipated patients.

each subject eats one cap of agar jelly shortly before having dinner every day for 4 weeks. at 0, 7th, 14th, 21th, and 28th day , the frequency of defecation and defecation condition is assessed.

Eligibility criteria:
inclusion criteria: * subjects take laxatives. exclusion criteria: * subjects underwent abdominal surgery.

Keywords: constipation, agar
efficacy and safety of olaparib in pretreated patients with measurable colorectal cancer, stratified by microsatellite instability (msi) status

Conditions: Colorectal Cancer

Summary: this study is being carried out to see if the new drug, olaparib (azd2281), can effectively and safely treat advanced large bowel cancer. the primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.


Eligibility criteria:
inclusion criteria: * patients will have measurable disseminated colorectal cancer that is incurable by surgery * patients will have had tumor progression following standard combination front-line or second-line chemotherapy. * crc patients who have relapsed or recurrent disease within six months after completing adjuvant or neoadjuvant chemotherapy exclusion criteria: * previous treatment with parp inhibitors, including olaparib. * patients with symptomatic, uncontrolled brain metastases. * patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used). * patients who are unable to swallow orally administered medication.

Keywords: colorectal cancer olaparib msi status stage iv measurable colorectal cancer stratified by msi status
effects of two types of concurrent training in functional performance and cognitive function of older adults

Conditions: Aging

Summary: the goal of this randomized controlled clinical trial is to identify and compare the impacts of traditional concurrent training and concurrent training consisting of strength training combined with dance classes on functional performance, cognitive function and quality of life in older people. the main question it aims to answer are: • the concurrent training consisting of strength training combined with dance classes can provide similar benefits to traditional concurrent training in neuromuscular and cardiorrespiratory performance, cognitive function and quality of life in older people? participants will training one of the two types of concurrent training (traditional concurrent training or concurrent training consisting of strength training combined with dance classes), two times a week, over 12 weeks. researchers will compare traditional concurrent training, concurrent training consisting of strength training combined with dance classes and a control group without exercise to see if this modalitys of physical exercise can provide increases in neuromuscular and cardiorrespiratory performance, cognitive function and quality of life in older people.


Eligibility criteria:
inclusion criteria: * be male or female aged between 65 and 75 years old * do not practice regular physical exercises for at least three months * no history of competitive sports throughout life * not having musculoskeletal and neurological diseases or disorders that may influence the performance of the exercises or affect the test results * not having health conditions in which physical exercise is contraindicated * achieve a score of no less than 24 on the mini mental state exam * achieve a score of up to 9.11 on the baecke physical activity questionnaire. exclusion criteria: * miss more than 20% of training sessions * miss more than three workouts in a row * failure to attend any of the evaluations will be excluded from the study.

Keywords: aging functional capacity physical activities
inst phase ii trial of gemcitabine and irinotecan in patients with relapsed or refractory lymphoma.

Conditions: Non-Hodgkin's Lymphoma; Cancer

Summary: primary objectives * assess the response rate in patients with recurrent or refractory b-cell nhl or hodgkins disease, treated with the combination of the gemcitabine and irinotecan. secondary objectives * assess progression free survival in these patients treated with this regimen. * assess toxicity of this regimen in this group of patients.

the purpose of the study is to see how well patients with relapsed or refractory lymphoma respond to treatment with gemcitabine and irinotecan. patients on this study take part because they have relapsed or refractory lymphoma. additionally, the study will assess treatment-related side effects and time until disease progression or recurrence.

Eligibility criteria:
inclusion criteria: 1. patients with a histologic diagnosis of non-hiv related b-cell nhl or hodgkins disease are eligible. 2. patients should have documented evidence of refractory or relapsed nhl or hodgkins disease for inclusion. 3. patient should have received 1 or more prior chemotherapeutic regimens for relapse, and should have completed last course of treatment at least 3 weeks prior to enrollment. 4. the patient must have bidimensionally measurable or evaluable disease. 5. age \> 18 years. 6. ecog performance status \< 2 7. informed consent. 8. anc \> 1.5, platelet count \> 100k, creatinine\< 2.0, bilirubin \< 3 9. female patients must have a negative pregnancy test.

Keywords: lymphoma-non hodgkins phase ii gemcitabine irinotecan
comparison of two fio2 (1 or 0.5) for tracheal extubation in post-anesthesia care unit

Conditions: Anesthesia; Atelectasis; Postoperative Complications; Hypoxemia; Hyperoxia

Summary: the purpose of the study is to assess the optimal fraction of inspired oxygen (0.5 or 1) for extubation or removal of a supraglottic airway device after general anesthesia.

during pre-anesthesia visit, eligible patients receive oral and written information of the study and potential risks. in the operating room all patients giving a written informed consent will undergo at the end of surgery a screening to determine eligibility for study entry. before emergence from general anesthesia, patients who meet the eligibility requirements will be randomized in a open label manner to receive a 0.5 or 1 fio2.

Eligibility criteria:
inclusion criteria: * patients undergoing general anesthesia, with invasive mechanical ventilation including an airway device (supraglottic airway device or tracheal tube) at their arrival in pacu. * asa physical status classification 1, 2, or 3 stabilized. * surgery performed in emergency operating room department including vascular, digestive, urological and minor trauma surgery or surgery performed in head and neck anesthesia pole block including anterior cervical spine, lumbar disc herniation, cranioplasty, nerve stimulator, vertebroplasty, narrow lumbar canal, simple arthrodesis (less than or equal to two stages), otological, ophthalmological and skin surgery. exclusion criteria: * per-operative hemodynamic instability. * patients with a bmi greater than 35. * patients classified as difficult to intubate and / or ventilate. * heavy surgeries (operating time greater than 4 hours). * patient requiring postoperative non invasive mechanical ventilation * patients with diagnosed copd * spo2 in room air \< 96% before the intervention. * any patient under guardianship. * pre-operative and / or intra-operative morphine intake. * surgical management of the upper airways (ex : tonsillectomy) * pregnant and lactating women.

Keywords: post-anesthesia care unit extubation
proton magnetic resonance spectroscopy of normal breast tissues in women volunteers

Conditions: Breast Neoplasms

Summary: magnetic resonance spectroscopy (mrs) is a diagnostic technique in mri that distinguishes various metabolites on the basis of their slightly different chemical shifts or resonance frequencies. the proton is the most abundant nucleus in the body. we will try to establish the typical proton mrs pattern of normal women breasts to be a guideline for future further investigations.

there are few reports regarding proton mrs in normal female breasts. the fibroglandular tissues and fat are the two major gross components in the breast. the water content in the fibroglandular tissues is much higher than that in the fat. there is still no documented report discussing proton mrs in normal female breasts of premenopausal and postmenopausal women. our study is to evaluate the proton mrs findings among normal premenopausal and postmenopausal women breasts, to find out if there are statistical differences on the main proton mrs patterns, water and lipid peak intensities and ratios between the two groups.

Eligibility criteria:
inclusion criteria: * women age ranged 30 years of age or older, with normal mammograms or ultrasound in recent 3 months exclusion criteria: * any women not fulfilling the inclusion criteria

Keywords: magnetic resonance imaging, breast disease
a study to evaluate the safety and pharmacokinetic of recombinant human coagulation factor viii ，fc fusion protein for injection

Conditions: Hemophilia A

Summary: primary objective: to assess the pharmacokinetics of recombinant human coagulation factor viii, fc fusion protein for injection (frsw107) secondary objectives: to assess safety and tolerability by monitoring fviii recovery and adverse events in severe hemophilia a.


Eligibility criteria:
key inclusion criteria: * the activity of the coagulation factor viii (fviii:c) \< 1%. less than 6 years old patients previously treated with fviii concentrate (s) for a minimum of 50 exposure days (eds) prior to study entry. 6 years old to 12 years old patients previously treated with fviii concentrate (s) for a minimum of 150 exposure days (eds) prior to study entry. * normal prothrombin time or inr \< 1.3. * negative lupus anticoagulant. key exclusion criteria: * hypersensitive to any of the excipients of the test materials (e.g. allergic to murine or hamster origin heterologous proteins). * history of hypersensitivity or anaphylaxis associated with any fviii or ii immunoglobulin administration. * current fviii inhibitor-positive or history of fviii inhibitor-positive. * other coagulation disorder(s) in addition to hemophilia a. * infusion of any products containing fviii within 72 h prior to administration. * significant hepatic or renal impairment (alt and ast \> 2×uln; serum bilirubin level \> 2 × upper limit of normal (uln), bun \> 2×uln, cr \> 2.0 uln). * one or more clinically significant tests for human immunodeficiency virus (hiv), antisyphilitic spirulina (tpha) and hepatitis c virus (hcv) antibody. * patients who received any anticoagulant or antiplatelet therapy within one week prior screening or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials. * patients having major surgery or receiving blood or bood components transfusion within 4 weeks prior screening or having planned major surgery schedule during the study. * patients who previously participated in the other clinical trials within one month prior to administration. * any life-threatening disease or condition which, according to the investigator's judgment, could not benefit from the trial participation. * patient who is considered by the other investigators not suitable for clinical study.

Keywords: hemophilia a;pharmacokinetics;child;safety and tolerability
a study of ly2951742 (galcanezumab) in japanese participants with migraine

Conditions: Migraine

Summary: the main purpose of this study is to evaluate the safety and effectiveness of the study drug known as galcanezumab in japanese participants with migraine.


Eligibility criteria:
inclusion criteria: * for episodic migraine participants: participants who completed the treatment period of galcanezumab study cgan. * have a diagnosis of chronic migraine as defined by international headache society (ihs) international classification of headache disorders (ichd)-3 beta guidelines (1.3) (ichd-3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50. exclusion criteria: * for chronic migraine participants: * are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product. * current use or prior exposure to galcanezumab or other antibodies of calcitonin gene-related peptide (cgrp) or its receptor. * known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab and the excipients in the investigational product. * history of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by ihs ichd-3 beta. * failure to respond to 3 or more adequately dosed migraine preventive treatments from different classes (that is, maximum tolerated dose for at least 2 months).

Keywords: prevention prophylaxis headache
influence of intra-abdominal ropivacaine 0.5% spray on postoperative analgesia in laparoscopic surgery.

Conditions: Pain, Acute

Summary: assessing postoperative pain after ropivacin 0.5% spray in the abdominal cavity during laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * appendectomy or cholecystectomy surgery exclusion criteria: * allergy to local anesthetics * intolerance to tramadol hcl * patient with peritonitis * pregnant women * surgery without laparoscopy * chronic pain before the operation
the effect of norethisterone enanthate on recurrent bacterial vaginosis

Conditions: Bacterial Vaginosis; HIV

Summary: the proposed study, hormonal contraception \& bv (hcbv), will investigate the effect of net-en and dmpa on recurrent bv, vaginal microbiota and inflammatory markers among women at high risk for hiv in kampala, uganda. the hypothesis is that net-en will show a similar beneficial effect on recurrent bv and vaginal microbiota as dmpa, without inducing signs of mucosal inflammation.

bacterial vaginosis (bv) is highly prevalent among women in africa and is associated with hiv acquisition. bv has been described as a dysbiosis, or a microbial imbalance, and is treated with metronidazole; however, once treated, it often recurs rapidly. developing robust treatment strategies to prevent recurrent bv is important for hiv prevention in key populations at high risk for hiv infection. there is evidence that hormonal contraceptives, including depot medroxyprogesterone acetate (dmpa), decrease bv recurrence; however, there is also evidence that dmpa increases the risk of hiv infection. encouraging women to start or switch to an alternative progestin injectable such as norethisterone enantate (net-en) may mitigate hiv risk whilst decreasing the risk of recurrent bv. to date, there are no published studies that have investigated the effect of net-en on vaginal microbiota. the proposed study will investigate the effect of net-en and dmpa on recurrent bv, vaginal microbiota and inflammatory markers among women at high risk for hiv in the good health for women project in kampala, uganda. consenting and eligible women will be treated for bv, and randomised to either net-en plus condoms or condoms only. women currently using dmpa will be enrolled as an observational comparison arm. all participants will be interviewed and examined; samples for vaginal microbiota, sexually transmitted infections, and inflammatory markers will be obtained. women will be followed up after 1 week, and 1, 2, 3, 4 and 6 months. the primary outcomes will be differences in vaginal microbiota clusters, time to recurrent bv, and inflammatory markers. qualitative research will be carried out to assess the acceptability of, and adherence to, net-en.

Eligibility criteria:
inclusion criteria: * bv positive by nugent score * hiv negative * capable of providing written informed consent exclusion criteria: * currently pregnant or using a reliable contraception (e.g. injectables, intrauterine devices, implant, oral contraceptive pills) * desiring pregnancy in the next year * history of tubal ligation or hysterectomy * contraindication to progestin-only contraceptives * unable to comprehend consent material because of language barrier or psychological difficulty
effects of different dietary regimens on tolerance acquisition in children with cow's milk allergy

Conditions: Cow's Milk Allergy

Summary: otherwise healthy infants (1-12 months of age at the diagnosis) with cma were prospectively evaluated. patients with cow's milk protein-induced anaphylaxis, eosinophilic disorders of the gastrointestinal tract, and food protein induced enterocolitic syndrome were excluded. a food challenge was performed 6 and 12 months after the diagnosis to assess clinical tolerance acquisition. main demographic and clinical characteristics were collected for each patient.


Eligibility criteria:
inclusion criteria: * otherwise healthy infants (1-12 months of age at the diagnosis) with cow's milk allergy were prospectively evaluated exclusion criteria: * patients with cow's milk protein-induced anaphylaxis, eosinophilic disorders of the gastrointestinal tract, and food protein induced enterocolitic syndrome were excluded.

Keywords: cow's milk allergy formulas probiotics
virtual reality pain control during burn wound care

Conditions: Burn

Summary: using virtual reality as a form of distraction during burn care.

the purpose of the study is to investigate the effectiveness of virtual reality (a form of distraction) in order to reduce patients' procedural burn pain.

Eligibility criteria:
inclusion criteria: * able to complete subjective evaluations of pain * english-speaking * not demonstrating delirium, psychosis, or any form of organic brain disorder * able to communicate orally exclusion criteria: * incapable of indicating subjective evaluation of pain * non-english-speaking * severe head or neck injury or other medical conditions that prohibit patient from wearing vr helmet * demonstrating delirium, psychosis, or organic brain disorder * unable to communicate verbally * significant developmental disability * extreme susceptibility to motion sickness * reports having no problem with pain during wound care.

Keywords: virtual reality distraction